From the Food and Drug Administration.
Schwetz
B A
BA
D000789:Angina, Unstable / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004485:Eczema / Q000188:drug therapy*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D014103:Torticollis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000925:Anticoagulants; D003879:Dermatologic Agents; D006629:Hirudins; D007166:Immunosuppressive Agents; D009465:Neuromuscular Agents; D010446:Peptide Fragments; D011994:Recombinant Proteins; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; C074619:bivalirudin; D016559:Tacrolimus